It’s hard not to compare ourselves with other people living with ANCA vasculitis who have benefited from medications and treatments. Comparing is human nature — and the cause of much suffering. It’s particularly hard when we’re experiencing a flare or side effects of our tough medication regimens. Seeing people…
Read more
A Phase 1 clinical trial assessing SC291, an experimental CAR T-cell therapy that Sana Biotechnology is developing for ANCA-associated vasculitis (AAV) and other autoimmune diseases, is recruiting patients at a number of sites across the U.S. Called GLEAM (NCT06294236), the study started enrolling up to…
A higher risk of death among AAV patients with interstitial lung disease (ILD) is significantly associated with older age, episodes of sudden symptom worsening, and microscopic polyangiitis (MPA), a common type of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). That’s according to a review of published studies that also pointed…
Becoming educated and informed about ANCA vasculitis is a good first step. Here you’ll find general information such as the diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your ANCA vasculitis journey.
There is no cure for ANCA vasculitis yet, but here you can find more information about current approved treatments, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
